| 1953 | Humans |
| 1203 | Male |
| 1063 | Female |
| 944 | Middle Aged |
| 913 | Aged |
| 621 | Parkinson Disease (physiopathology) |
| 547 | Animals |
| 472 | Parkinson Disease (drug therapy) |
| 419 | Adult |
| 382 | Parkinson Disease (therapy) |
| 324 | Parkinson Disease (complications) |
| 260 | Parkinson Disease (pathology) |
| 245 | Parkinson Disease (metabolism) |
| 231 | Aged, 80 and over |
| 225 | Antiparkinson Agents (therapeutic use) |
| 208 | Parkinson Disease (genetics) |
| 205 | Levodopa (therapeutic use) |
| 195 | Parkinson Disease (psychology) |
| 184 | Disease Models, Animal |
| 180 | Treatment Outcome |
| 168 | Rats |
| 153 | Parkinson Disease (diagnosis) |
| 143 | Dopamine (metabolism) |
| 137 | Neuropsychological Tests |
| 132 | Antiparkinson Agents (adverse effects) |
| 123 | Severity of Illness Index |
| 123 | Levodopa (adverse effects) |
| 115 | Subthalamic Nucleus (physiology) |
| 111 | Mice |
| 107 | Deep Brain Stimulation (methods) |
| 106 | Parkinson Disease (epidemiology) |
| 101 | Case-Control Studies |
| 96 | Time Factors |
| 96 | France |
| 93 | Follow-Up Studies |
| 89 | Subthalamic Nucleus (physiopathology) |
| 89 | Parkinson Disease (surgery) |
| 87 | Neurons (metabolism) |
| 82 | Electrodes, Implanted |
| 82 | Deep Brain Stimulation |
| 79 | Parkinson Disease, Secondary (chemically induced) |
| 78 | Magnetic Resonance Imaging |
| 77 | Adolescent |
| 74 | Risk Factors |
| 73 | Substantia Nigra (pathology) |
| 73 | Prospective Studies |
| 71 | Electric Stimulation Therapy |
| 71 | Brain (pathology) |
| 70 | Antiparkinson Agents (administration & dosage) |
| 68 | Neurons (pathology) |
| 68 | Double-Blind Method |
| 67 | Parkinson Disease (etiology) |
| 67 | Parkinson Disease (diagnostic imaging) |
| 67 | Neurons (physiology) |
| 67 | Corpus Striatum (metabolism) |
| 65 | Dopamine (physiology) |
| 65 | Brain (metabolism) |
| 63 | Retrospective Studies |
| 62 | Substantia Nigra (metabolism) |
| 62 | Analysis of Variance |
| 61 | Rats, Sprague-Dawley |
| 61 | Levodopa (pharmacology) |
| 61 | Dose-Response Relationship, Drug |
| 60 | Levodopa (administration & dosage) |
| 60 | Disease Progression |
| 60 | Brain (physiopathology) |
| 59 | Immunohistochemistry |
| 58 | Antiparkinson Agents (pharmacology) |
| 55 | Dopamine Agonists (therapeutic use) |
| 54 | Reference Values |
| 53 | Rats, Wistar |
| 52 | Tyrosine 3-Monooxygenase (metabolism) |
| 51 | Movement (physiology) |
| 51 | Diagnosis, Differential |
| 50 | Subthalamic Nucleus (surgery) |
| 50 | Child |
| 49 | Neurons (drug effects) |
| 49 | Mice, Inbred C57BL |
| 49 | Deep Brain Stimulation (adverse effects) |
| 49 | Brain Mapping |
| 47 | Surveys and Questionnaires |
| 47 | Parkinson Disease, Secondary (physiopathology) |
| 46 | Young Adult |
| 45 | Dyskinesia, Drug-Induced (etiology) |
| 45 | Cognition Disorders (etiology) |
| 45 | Basal Ganglia (physiopathology) |
| 44 | France (epidemiology) |
| 43 | Stereotaxic Techniques |
| 43 | Reproducibility of Results |
| 43 | Electrocardiography |
| 43 | Cross-Sectional Studies |
| 42 | Mutation |
| 42 | Age of Onset |
| 40 | Drug Therapy, Combination |
| 40 | Age Factors |
| 39 | Reaction Time (physiology) |
| 39 | Quality of Life |
| 39 | Genotype |
| 38 | Psychomotor Performance (physiology) |
| 38 | Oxidopamine |
| 38 | Neurologic Examination |
| 38 | Motor Activity (drug effects) |
| 38 | Corpus Striatum (pathology) |
| 37 | Substantia Nigra (physiopathology) |
| 37 | Statistics, Nonparametric |
| 37 | Prevalence |
| 37 | Corpus Striatum (drug effects) |
| 36 | Dyskinesia, Drug-Induced (physiopathology) |
| 35 | alpha-Synuclein (metabolism) |
| 35 | Globus Pallidus (physiopathology) |
| 35 | Genetic Predisposition to Disease |
| 35 | Electromyography |
| 34 | Macaca fascicularis |
| 34 | Corpus Striatum (physiopathology) |
| 33 | Wolff-Parkinson-White Syndrome (physiopathology) |
| 33 | Tomography, Emission-Computed, Single-Photon |
| 33 | Psychiatric Status Rating Scales |
| 33 | Mutation (genetics) |
| 33 | Clinical Trials as Topic |
| 32 | Motor Activity (physiology) |
| 32 | Magnetic Resonance Imaging (methods) |
| 32 | Cohort Studies |
| 31 | Neuroprotective Agents (therapeutic use) |
| 31 | Gait Disorders, Neurologic (etiology) |
| 31 | Electric Stimulation |
| 31 | Brain (drug effects) |
| 30 | Parkinson Disease, Secondary (pathology) |
| 30 | Nerve Degeneration (pathology) |
| 30 | Functional Laterality |
| 30 | Functional Laterality (physiology) |
| 30 | Electric Stimulation Therapy (methods) |
| 30 | Dopamine Agonists (adverse effects) |
| 29 | Wolff-Parkinson-White Syndrome (surgery) |
| 29 | Positron-Emission Tomography |
| 29 | Motor Cortex (physiopathology) |
| 29 | Electroencephalography |
| 29 | Disability Evaluation |
| 28 | Ubiquitin-Protein Ligases (genetics) |
| 28 | Mice, Knockout |
| 28 | Electrophysiology |
| 27 | Mesencephalon (pathology) |
| 27 | Dyskinesia, Drug-Induced (drug therapy) |
| 27 | Dopamine Agonists (pharmacology) |
| 27 | Dopamine Agents (therapeutic use) |
| 27 | Combined Modality Therapy |
| 27 | Cognition Disorders (diagnosis) |
| 27 | Activities of Daily Living |
| 27 | 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine |
| 26 | Subthalamic Nucleus (pathology) |
| 26 | Substantia Nigra (drug effects) |
| 26 | Protein-Serine-Threonine Kinases (genetics) |
| 26 | Predictive Value of Tests |
| 26 | Phenotype |
| 26 | Parkinson Disease (enzymology) |
| 26 | Neural Pathways (physiopathology) |
| 26 | Nerve Tissue Proteins (genetics) |
| 26 | Models, Neurological |
| 26 | Dopaminergic Neurons (metabolism) |
| 26 | Basal Ganglia (pathology) |
| 25 | alpha-Synuclein (genetics) |
| 25 | Wolff-Parkinson-White Syndrome (diagnosis) |
| 25 | Tomography, Emission-Computed |
| 25 | Reaction Time |
| 25 | Mesencephalon (metabolism) |
| 25 | Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 |
| 25 | Cognition (physiology) |
| 25 | Basal Ganglia (metabolism) |
| 24 | Prognosis |
| 24 | Neuroprotective Agents (pharmacology) |
| 24 | Gait (physiology) |
| 24 | Electric Stimulation Therapy (adverse effects) |
| 24 | Dopamine Agonists (administration & dosage) |
| 24 | Cells, Cultured |
| 24 | Behavior, Animal (drug effects) |
| 23 | Sensitivity and Specificity |
| 23 | Pedigree |
| 23 | Parkinson Disease, Secondary (drug therapy) |
| 23 | Parkinson Disease (blood) |
| 23 | Movement Disorders (physiopathology) |
| 23 | Models, Biological |
| 23 | Incidence |
| 23 | Frontal Lobe (physiopathology) |
| 23 | Depression (etiology) |
| 23 | Brain (diagnostic imaging) |
| 22 | Tremor (therapy) |
| 22 | Polysomnography |
| 22 | Comorbidity |
| 22 | Child, Preschool |
| 22 | Cerebral Cortex (physiopathology) |
| 21 | Tyrosine 3-Monooxygenase (analysis) |
| 21 | Posture |
| 21 | Image Processing, Computer-Assisted |
| 21 | Gait Disorders, Neurologic (physiopathology) |
| 21 | Dementia (diagnosis) |
| 21 | Cognition |
| 21 | Cognition Disorders (physiopathology) |
| 21 | Alzheimer Disease (physiopathology) |
| 21 | Alzheimer Disease (metabolism) |
| 20 | Thalamic Nuclei (physiopathology) |
| 20 | RNA, Messenger (metabolism) |
| 20 | Pilot Projects |
| 20 | Parkinsonian Disorders (metabolism) |
| 20 | Parkinson Disease (history) |
| 20 | Neurons (cytology) |
| 20 | Movement |
| 20 | In Situ Hybridization |
| 20 | Drug Administration Schedule |
| 20 | Dopaminergic Neurons (drug effects) |
| 20 | Bromocriptine (therapeutic use) |
| 20 | Alzheimer Disease (pathology) |
| 19 | Tremor (physiopathology) |
| 19 | Subthalamic Nucleus |
| 19 | Parkinsonian Disorders (pathology) |
| 19 | Movement Disorders (therapy) |
| 19 | Movement Disorders (etiology) |
| 19 | Mitochondria (metabolism) |
| 19 | Lewy Bodies (pathology) |
| 19 | History, 20th Century |
| 19 | History, 19th Century |
| 19 | Europe |
| 19 | Deep Brain Stimulation (instrumentation) |
| 19 | Apomorphine (pharmacology) |
| 19 | Apomorphine (administration & dosage) |
| 18 | Nerve Net (physiopathology) |
| 18 | Mice, Transgenic |
| 18 | Longitudinal Studies |
| 18 | Facial Expression |
| 18 | DNA Mutational Analysis |
| 18 | Cell Death (physiology) |
| 18 | Behavior, Animal |
| 18 | Apomorphine (therapeutic use) |
| 18 | 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (pharmacology) |
| 17 | Synucleins |
| 17 | Subthalamic Nucleus (metabolism) |
| 17 | Signal Transduction |
| 17 | Sex Factors |
| 17 | Psychomotor Performance (drug effects) |
| 17 | Postural Balance (physiology) |
| 17 | Parkinsonian Disorders (physiopathology) |
| 17 | Oxidopamine (toxicity) |
| 17 | Globus Pallidus (surgery) |
| 17 | Genetic Predisposition to Disease (genetics) |
| 17 | Cross-Over Studies |
| 17 | Cognition Disorders (psychology) |
| 17 | Cell Count |
| 17 | Catheter Ablation |
| 17 | Biomechanical Phenomena |
| 17 | Attention (physiology) |
| 16 | alpha-Synuclein |
| 16 | Thalamus (surgery) |
| 16 | Photic Stimulation |
| 16 | Parkinson Disease, Secondary (metabolism) |
| 16 | Neurosurgical Procedures |
| 16 | Neurons (enzymology) |
| 16 | Neurodegenerative Diseases (physiopathology) |
| 16 | Multivariate Analysis |
| 16 | Macaca mulatta |
| 16 | Kinetics |
| 16 | Iron (metabolism) |
| 16 | Dyskinesias (etiology) |
| 16 | Dopaminergic Neurons (pathology) |
| 16 | Dopamine Agents (adverse effects) |
| 16 | Dominance, Cerebral (physiology) |
| 16 | Dementia (complications) |
| 16 | Brain (physiology) |
| 16 | Basal Ganglia (physiology) |
| 15 | tau Proteins (genetics) |
| 15 | Ubiquitin-Protein Ligases (metabolism) |
| 15 | Substantia Nigra (cytology) |
| 15 | Regression Analysis |
| 15 | Receptors, Dopamine (metabolism) |
| 15 | REM Sleep Behavior Disorder (physiopathology) |
| 15 | Posture (physiology) |
| 15 | Neurologic Examination (drug effects) |
| 15 | Nerve Tissue Proteins (metabolism) |
| 15 | Motor Activity |
| 15 | Molecular Sequence Data |
| 15 | Memory (physiology) |
| 15 | Family Health |
| 15 | Emotions |
| 15 | Emotions (physiology) |
| 15 | Drug Interactions |
| 15 | Dopamine Plasma Membrane Transport Proteins |
| 15 | Dementia (pathology) |
| 15 | Dementia (etiology) |
| 15 | Cell Death |
| 15 | Antipsychotic Agents (adverse effects) |
| 15 | Algorithms |
| 14 | Wolff-Parkinson-White Syndrome (complications) |
| 14 | United States |
| 14 | Tyrosine 3-Monooxygenase (genetics) |
| 14 | Tremor (etiology) |
| 14 | Tomography, X-Ray Computed |
| 14 | Statistics as Topic |
| 14 | Psychomotor Performance |
| 14 | Postural Balance |
| 14 | Phosphorylation |
| 14 | Parkinsonian Disorders (drug therapy) |
| 14 | Parkinson Disease (rehabilitation) |
| 14 | Oxidopamine (pharmacology) |
| 14 | Odds Ratio |
| 14 | Neurodegenerative Diseases (metabolism) |
| 14 | Neural Pathways (pathology) |
| 14 | Nerve Degeneration (physiopathology) |
| 14 | MPTP Poisoning |
| 14 | Gait |
| 14 | Gait Disorders, Neurologic (therapy) |
| 14 | Electric Stimulation Therapy (instrumentation) |
| 14 | Dyskinesia, Drug-Induced (metabolism) |
| 14 | Dopamine Plasma Membrane Transport Proteins (metabolism) |
| 14 | Dopamine Agents (pharmacology) |
| 14 | Denervation |
| 14 | Dementia (psychology) |
| 14 | Bromocriptine (adverse effects) |
| 14 | Brain Mapping (methods) |
| 14 | Antiparkinson Agents (pharmacokinetics) |
| 13 | alpha-Synuclein (chemistry) |
| 13 | Task Performance and Analysis |
| 13 | Subthalamic Nucleus (radiation effects) |
| 13 | Subthalamic Nucleus (drug effects) |
| 13 | Serotonin (metabolism) |
| 13 | Recognition (Psychology) (physiology) |
| 13 | Receptors, Dopamine D2 (physiology) |
| 13 | Protein Kinases (genetics) |
| 13 | Patient Selection |
| 13 | Parkinsonian Disorders (genetics) |
| 13 | Parkinson Disease, Secondary (etiology) |
| 13 | Oxidative Stress |
| 13 | Neurodegenerative Diseases (genetics) |
| 13 | Nerve Degeneration (metabolism) |
| 13 | Muscle, Skeletal (physiopathology) |
| 13 | Mental Status Schedule |
| 13 | Membrane Glycoproteins |
| 13 | Globus Pallidus (physiology) |
| 13 | Genetic Therapy (methods) |
| 13 | Gait Disorders, Neurologic (drug therapy) |
| 13 | Depression (psychology) |
| 13 | Cortical Synchronization |
| 13 | Cell Line |
| 13 | Blood Pressure (drug effects) |
| 13 | Basal Ganglia (drug effects) |
| 13 | Autoradiography |
| 13 | Apoptosis |
| 13 | Apoptosis (physiology) |
| 13 | Apathy (physiology) |
| 13 | Alzheimer Disease (genetics) |
| 12 | Supranuclear Palsy, Progressive (physiopathology) |
| 12 | Receptors, Dopamine (physiology) |
| 12 | Quality of Life (psychology) |
| 12 | Protein Kinases (metabolism) |
| 12 | Polymorphism, Single Nucleotide (genetics) |
| 12 | Polymerase Chain Reaction |
| 12 | Parkinson Disease, Secondary (diagnosis) |
| 12 | Neurons (chemistry) |
| 12 | Neuronal Plasticity (physiology) |
| 12 | Nerve Degeneration |
| 12 | Multiple System Atrophy (physiopathology) |
| 12 | Movement (drug effects) |
| 12 | Motor Cortex (physiology) |
| 12 | Motivation |
| 12 | Memory Disorders (etiology) |
| 12 | Logistic Models |
| 12 | Infant |
| 12 | Heart Rate (drug effects) |
| 12 | Globus Pallidus (pathology) |
| 12 | Genetic Therapy |
| 12 | Gene Expression Regulation |
| 12 | Gene Expression Regulation (drug effects) |
| 12 | Dyskinesia, Drug-Induced (therapy) |
| 12 | Dyskinesia, Drug-Induced (prevention & control) |
| 12 | Depressive Disorder (psychology) |
| 12 | Confidence Intervals |
| 12 | Cognition (drug effects) |
| 12 | Cerebral Cortex (pathology) |
| 12 | Blotting, Western |
| 12 | Alzheimer Disease (psychology) |
| 11 | Transcription Factors (genetics) |
| 11 | Synaptic Transmission (physiology) |
| 11 | Supranuclear Palsy, Progressive (diagnosis) |
| 11 | Subthalamic Nucleus (anatomy & histology) |
| 11 | Substantia Nigra (chemistry) |
| 11 | Receptors, Dopamine D2 (agonists) |
| 11 | Reaction Time (drug effects) |
| 11 | Randomized Controlled Trials as Topic |
| 11 | Radionuclide Imaging |
| 11 | ROC Curve |
| 11 | Putamen (metabolism) |
| 11 | Polymorphism, Single Nucleotide |
| 11 | Polymorphism, Genetic |
| 11 | Parkinson Disease |
| 11 | Parkinson Disease (mortality) |
| 11 | Neurosurgical Procedures (methods) |
| 11 | Neurodegenerative Diseases (pathology) |
| 11 | Neural Pathways (metabolism) |
| 11 | Movement Disorders (drug therapy) |
| 11 | Mitochondria (physiology) |
| 11 | Mesencephalon (cytology) |
| 11 | Mental Disorders (etiology) |
| 11 | Lewy Bodies (metabolism) |
| 11 | Iodine Radioisotopes |
| 11 | Indoles (therapeutic use) |
| 11 | Indans (therapeutic use) |
| 11 | Heart Conduction System (physiopathology) |
| 11 | Haplorhini |
| 11 | Hallucinations (etiology) |
| 11 | Glutamic Acid (metabolism) |
| 11 | Globus Pallidus (metabolism) |
| 11 | Gene Frequency |
| 11 | Dopamine Antagonists (pharmacology) |
| 11 | Dopamine Agents |
| 11 | Dementia (physiopathology) |
| 11 | Cues |
| 11 | Cognition Disorders (epidemiology) |
| 11 | Chronic Disease |
| 11 | Chromatography, High Pressure Liquid |
| 11 | Cell Survival |
| 11 | Cell Line, Tumor |
| 11 | Calcium (metabolism) |
| 11 | Brain Chemistry |
| 11 | Attention |
| 11 | Amino Acid Sequence |
| 11 | Alzheimer Disease (diagnosis) |
| 11 | Aging (physiology) |
| 11 | Age Distribution |
| 11 | Action Potentials (physiology) |
| 11 | 3,4-Dihydroxyphenylacetic Acid (metabolism) |
| 10 | tau Proteins (metabolism) |
| 10 | Transcranial Magnetic Stimulation |
| 10 | Reward |
| 10 | Receptors, Dopamine D2 (metabolism) |
| 10 | Receptors, Dopamine D1 (metabolism) |
| 10 | Receptors, Dopamine (drug effects) |
| 10 | REM Sleep Behavior Disorder (diagnosis) |
| 10 | Positron-Emission Tomography (methods) |
| 10 | Piribedil (therapeutic use) |
| 10 | Parkinsonian Disorders (therapy) |
| 10 | Paris |
| 10 | Neurons (transplantation) |
| 10 | Neural Pathways (physiology) |
| 10 | Nerve Tissue Proteins |
| 10 | Muscle Rigidity (etiology) |
| 10 | Multiple System Atrophy (pathology) |
| 10 | Macaca |
| 10 | MPTP Poisoning (physiopathology) |
| 10 | Indans (adverse effects) |
| 10 | Hypotension, Orthostatic (etiology) |
| 10 | Homovanillic Acid (metabolism) |
| 10 | Heterozygote |
| 10 | Heart Conduction System (surgery) |
| 10 | Glucose (metabolism) |
| 10 | Fluorodeoxyglucose F18 |
| 10 | Europe (epidemiology) |
| 10 | Electrophysiologic Techniques, Cardiac |
| 10 | Dystonia (physiopathology) |
| 10 | Dysarthria (etiology) |
| 10 | Drug Combinations |
| 10 | Dopamine (deficiency) |
| 10 | Cognition Disorders (complications) |
| 10 | Carrier Proteins (genetics) |
| 10 | Brain (blood supply) |
| 10 | Binding Sites |
| 10 | Apathy |
| 10 | Administration, Oral |
| 10 | 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (administration & dosage) |
| 9 | Wolff-Parkinson-White Syndrome (epidemiology) |
| 9 | Visual Perception |
| 9 | Sympatholytics |
| 9 | Supranuclear Palsy, Progressive (pathology) |
| 9 | Sleep Wake Disorders (etiology) |
| 9 | Signal Transduction (physiology) |
| 9 | Sex Distribution |
| 9 | Selegiline (therapeutic use) |
| 9 | Receptors, Dopamine D2 (drug effects) |
| 9 | Radiopharmaceuticals |
| 9 | RNA, Messenger (analysis) |
| 9 | REM Sleep Behavior Disorder (etiology) |
| 9 | REM Sleep Behavior Disorder (complications) |
| 9 | Proto-Oncogene Proteins c-fos (metabolism) |
| 9 | Point Mutation |
| 9 | Photic Stimulation (methods) |
| 9 | Parkinsonian Disorders (complications) |
| 9 | Parkinson Disease (economics) |
| 9 | Pain (etiology) |
| 9 | Oxidopamine (administration & dosage) |
| 9 | Muscle Rigidity (physiopathology) |
| 9 | Multiple System Atrophy (diagnosis) |
| 9 | Motor Neurons (physiology) |
| 9 | Mitochondria (drug effects) |
| 9 | Mental Recall (physiology) |
| 9 | Memory |
| 9 | Membrane Transport Proteins |
| 9 | Levodopa (toxicity) |
| 9 | Injections, Subcutaneous |
| 9 | Inflammation (pathology) |
| 9 | Glutamate Decarboxylase (genetics) |
| 9 | Gait (drug effects) |
| 9 | Executive Function (physiology) |
| 9 | Dopaminergic Neurons (physiology) |
| 9 | Depression (epidemiology) |
| 9 | Dementia (genetics) |
